Last reviewed · How we verify
Trastuzumab in combination with pertuzumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Trastuzumab in combination with pertuzumab (Trastuzumab in combination with pertuzumab) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trastuzumab in combination with pertuzumab TARGET | Trastuzumab in combination with pertuzumab | Cancer Research UK | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trastuzumab in combination with pertuzumab CI watch — RSS
- Trastuzumab in combination with pertuzumab CI watch — Atom
- Trastuzumab in combination with pertuzumab CI watch — JSON
- Trastuzumab in combination with pertuzumab alone — RSS
Cite this brief
Drug Landscape (2026). Trastuzumab in combination with pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-in-combination-with-pertuzumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab